This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ira J. Dunkel, MD; James B. Bussel, MD

Am J Dis Child. 1993;147(9):994-1000.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Increased attention has been devoted to the management of neutropenia during the last 2 to 4 years. In this review we will discuss the introduction of effective novel therapies: hematopoietic growth factors (HGFs) for many forms of persistent neutropenia and intravenous (IV) immune globulin for autoimmune neutropenia (AIN).

Neutropenia is defined as a subnormal absolute number of neutrophils circulating in the blood. Determination of the absolute neutrophil count (ANC) requires the combination of a white blood cell (WBC) count and a differential WBC count. For example, if the WBC count is 8.0x10⁹/L and the differential WBC count indicates 0.20 neutrophils, the ANC=8.0x0.20, or 1.6. Since the differential WBC count defines neutropenia, it is important that a hematologist review the blood smear and that an automated count not be exclusively relied on. The exact definition of the boundary between a normal ANC and neutropenia has ranged between 1.5 and . . . [Full Text PDF of this Article]

Author Affiliations
From the Departments of Pediatrics, Cornell Medical Center and Memorial Sloan-Kettering Cancer Center, New York, NY.

Footnotes
Accepted for publication January 8, 1993.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?